$SBRA
Sabra Health Care REIT, Inc.

2024 Q2 Form 10-Q Financial Statement

#000149229824000014 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $176.1M $166.7M
YoY Change 9.29% 3.36%
Cost Of Revenue $50.36M $49.67M
YoY Change 14.54% 13.82%
Gross Profit $125.8M $117.1M
YoY Change 7.32% -0.52%
Gross Profit Margin 71.41% 70.21%
Selling, General & Admin $12.58M $11.75M
YoY Change 26.29% 14.17%
% of Gross Profit 10.0% 10.04%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $41.68M $42.91M
YoY Change -5.58% -18.77%
% of Gross Profit 33.14% 36.65%
Operating Expenses $58.66M $58.99M
YoY Change -0.37% -12.33%
Operating Profit $67.13M $58.09M
YoY Change 15.09% 15.26%
Interest Expense -$29.23M -$29.00M
YoY Change 0.87% -1.28%
% of Operating Profit -43.55% -49.93%
Other Income/Expense, Net $1.854M $760.0K
YoY Change -123.67% -103.35%
Pretax Income $24.33M $27.30M
YoY Change 9.77% -444.68%
Income Tax $437.0K $453.0K
% Of Pretax Income 1.8% 1.66%
Net Earnings $23.98M $26.25M
YoY Change 13.15% -376.74%
Net Earnings / Revenue 13.61% 15.74%
Basic Earnings Per Share $0.10 $0.11
Diluted Earnings Per Share $0.10 $0.11
COMMON SHARES
Basic Shares Outstanding 231.5M shares 231.5M shares
Diluted Shares Outstanding 233.8M shares 233.4M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.40M $59.93M
YoY Change 33.65% 78.72%
Cash & Equivalents $36.40M $59.93M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $171.8M $196.9M
YoY Change -1.17% 18.44%
LONG-TERM ASSETS
Property, Plant & Equipment $4.577B $4.589B
YoY Change -3.68% -4.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $129.8M $132.0M
YoY Change -7.57% -5.29%
Other Assets $5.911M $6.003M
YoY Change 14.87% 16.52%
Total Long-Term Assets $5.179B $5.178B
YoY Change -3.2% -3.94%
TOTAL ASSETS
Total Short-Term Assets $171.8M $196.9M
Total Long-Term Assets $5.179B $5.178B
Total Assets $5.351B $5.374B
YoY Change -3.14% -3.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $83.23M $79.06M
YoY Change -21.08% -34.98%
Accrued Expenses $29.60M $33.70M
YoY Change 80.49% 57.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $112.8M $112.8M
YoY Change -7.41% -21.15%
LONG-TERM LIABILITIES
Long-Term Debt $2.447B $2.463B
YoY Change 1.1% 2.79%
Other Long-Term Liabilities $29.69M $31.12M
YoY Change -23.24% -23.1%
Total Long-Term Liabilities $2.476B $2.495B
YoY Change 0.72% 2.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $112.8M $112.8M
Total Long-Term Liabilities $2.476B $2.495B
Total Liabilities $2.589B $2.607B
YoY Change 0.33% 1.05%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $2.343M $2.315M
YoY Change 1.34% 0.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.762B $2.767B
YoY Change
Total Liabilities & Shareholders Equity $5.351B $5.374B
YoY Change -3.14% -3.27%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $23.98M $26.25M
YoY Change 13.15% -376.74%
Depreciation, Depletion And Amortization $41.68M $42.91M
YoY Change -5.58% -18.77%
Cash From Operating Activities $80.13M $52.80M
YoY Change 13.93% -22.69%
INVESTING ACTIVITIES
Capital Expenditures $36.13M $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$21.18M -$13.22M
YoY Change 158.5% -108.65%
Cash From Investing Activities -$57.31M -$13.22M
YoY Change 599.46% -111.68%
FINANCING ACTIVITIES
Cash Dividend Paid $69.44M
YoY Change 0.13%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -46.41M -$20.23M
YoY Change -32.22% -89.68%
NET CHANGE
Cash From Operating Activities 80.13M $52.80M
Cash From Investing Activities -57.31M -$13.22M
Cash From Financing Activities -46.41M -$20.23M
Net Change In Cash -23.59M $19.34M
YoY Change 272.29% -232.42%
FREE CASH FLOW
Cash From Operating Activities $80.13M $52.80M
Capital Expenditures $36.13M $0.00
Free Cash Flow $44.00M $52.80M
YoY Change -37.44% 84.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#HealthCareResidentServiceMember
CY2023Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#HealthCareResidentServiceMember
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://www.sabrahealth.com/20240331#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://www.sabrahealth.com/20240331#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2023Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2024Q1 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2024Q1 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://www.sabrahealth.com/20240331#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2023Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBank
CY2024Q1 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://www.sabrahealth.com/20240331#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2023Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBank
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
66031000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56721000 usd
CY2024Q1 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
8940000 usd
CY2023Q1 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
8733000 usd
CY2024Q1 us-gaap Revenues
Revenues
166747000 usd
CY2023Q1 us-gaap Revenues
Revenues
161324000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42914000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52827000 usd
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
28408000 usd
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
28540000 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11890000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10502000 usd
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-137000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-208000 usd
CY2024Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
3137000 usd
CY2023Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
7064000 usd
CY2024Q1 sbra Operating And Interest Expense
OperatingAndInterestExpense
140205000 usd
CY2023Q1 sbra Operating And Interest Expense
OperatingAndInterestExpense
146530000 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1541000 usd
CY2024Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
760000 usd
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
341000 usd
CY2024Q1 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
0 usd
CY2023Q1 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-21515000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
760000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22715000 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
27302000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7921000 usd
CY2024Q1 sbra Income Loss From Equity Method Investments And Other Than Temporary Impairment
IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment
-595000 usd
CY2023Q1 sbra Income Loss From Equity Method Investments And Other Than Temporary Impairment
IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment
-838000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
453000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
728000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
26254000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231453564 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231164876 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
233365031 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231164876 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
26254000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1498000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1623000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
8948000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-2000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7450000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1625000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
33704000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11112000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3056395000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1625000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2675000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-1933000 usd
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
69798000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2976227000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2802534000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
26254000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7450000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3049000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-2139000 usd
CY2024Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2024Q1 us-gaap Dividends Common Stock
DividendsCommonStock
69974000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2767174000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
26254000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42914000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52827000 usd
CY2024Q1 sbra Non Cash Rental And Related Revenues Adjustments
NonCashRentalAndRelatedRevenuesAdjustments
591000 usd
CY2023Q1 sbra Non Cash Rental And Related Revenues Adjustments
NonCashRentalAndRelatedRevenuesAdjustments
-2398000 usd
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-7000 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
392000 usd
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3071000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3014000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2521000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2229000 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1541000 usd
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-137000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-208000 usd
CY2024Q1 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
0 usd
CY2023Q1 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-21515000 usd
CY2024Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
3137000 usd
CY2023Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
7064000 usd
CY2024Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-595000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-838000 usd
CY2024Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
1478000 usd
CY2023Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
367000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6288000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2782000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-21348000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5839000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
52795000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
68289000 usd
CY2024Q1 us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
0 usd
CY2023Q1 us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
39630000 usd
CY2024Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
102000 usd
CY2023Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
1800000 usd
CY2024Q1 sbra Payments For Preferred Equity Investments
PaymentsForPreferredEquityInvestments
1007000 usd
CY2023Q1 sbra Payments For Preferred Equity Investments
PaymentsForPreferredEquityInvestments
6384000 usd
CY2024Q1 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
12935000 usd
CY2023Q1 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
19540000 usd
CY2024Q1 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
391000 usd
CY2023Q1 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
6144000 usd
CY2024Q1 sbra Repayments Of Preferred Equity Investments
RepaymentsOfPreferredEquityInvestments
-617000 usd
CY2023Q1 sbra Repayments Of Preferred Equity Investments
RepaymentsOfPreferredEquityInvestments
-1433000 usd
CY2024Q1 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
188000 usd
CY2023Q1 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
4797000 usd
CY2024Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0 usd
CY2023Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
152259000 usd
CY2024Q1 us-gaap Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity
ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
0 usd
CY2023Q1 us-gaap Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity
ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
25490000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13224000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
113175000 usd
CY2024Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
52404000 usd
CY2023Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-118442000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Medium Term Notes
ProceedsFromIssuanceOfMediumTermNotes
0 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Medium Term Notes
ProceedsFromIssuanceOfMediumTermNotes
12186000 usd
CY2024Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
503000 usd
CY2023Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
490000 usd
CY2024Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
80000 usd
CY2023Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
18127000 usd
CY2024Q1 sbra Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees
ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees
-2606000 usd
CY2023Q1 sbra Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees
ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees
-1847000 usd
CY2024Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
69444000 usd
CY2023Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
69351000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-20229000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-196071000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
19342000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14607000 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-131000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-641000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46719000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53932000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65930000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38684000 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
20495000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
22318000 usd
CY2024Q1 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
0 usd
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
4644000 usd
CY2024Q1 us-gaap Equity Method Investments
EquityMethodInvestments
132022000 usd
CY2024Q1 sbra Real Estate Investments Joint Ventures Number
RealEstateInvestmentsJointVenturesNumber
0 investment
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div>
CY2024Q1 sbra Business Acquisition Number Of Acquired Properties
BusinessAcquisitionNumberOfAcquiredProperties
0 property
CY2024Q1 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5636723000 usd
CY2024Q1 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1059405000 usd
CY2024Q1 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4577318000 usd
CY2023Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5638347000 usd
CY2023Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1021086000 usd
CY2023Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4617261000 usd
CY2024Q1 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
4843475000 usd
CY2023Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
4843258000 usd
CY2024Q1 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
239086000 usd
CY2023Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
238185000 usd
CY2024Q1 us-gaap Land Improvements
LandImprovements
10253000 usd
CY2023Q4 us-gaap Land Improvements
LandImprovements
10306000 usd
CY2024Q1 us-gaap Land
Land
543909000 usd
CY2023Q4 us-gaap Land
Land
546598000 usd
CY2024Q1 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5636723000 usd
CY2023Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5638347000 usd
CY2024Q1 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1059405000 usd
CY2023Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1021086000 usd
CY2024Q1 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4577318000 usd
CY2023Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4617261000 usd
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000000 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
136843000 usd
CY2023Q1 sbra Disposal Group Including Discontinued Operations Number Of Properties
DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties
8 facility
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
160300000 usd
CY2023Q1 sbra Disposal Group Including Discontinued Operation Assets And Liabilities Net
DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet
181800000 usd
CY2023Q1 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-21500000 usd
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-22100000 usd
CY2024Q1 us-gaap Security Deposit Liability
SecurityDepositLiability
8000000 usd
CY2023Q4 us-gaap Security Deposit Liability
SecurityDepositLiability
16400000 usd
CY2024Q1 sbra Letters Of Credit Deposits
LettersOfCreditDeposits
64000000 usd
CY2023Q4 sbra Letters Of Credit Deposits
LettersOfCreditDeposits
56000000 usd
CY2024Q1 sbra Property Taxes Insurance And Tenant Improvement Deposit Liability
PropertyTaxesInsuranceAndTenantImprovementDepositLiability
12000000 usd
CY2023Q4 sbra Property Taxes Insurance And Tenant Improvement Deposit Liability
PropertyTaxesInsuranceAndTenantImprovementDepositLiability
12400000 usd
CY2024Q1 us-gaap Variable Lease Income
VariableLeaseIncome
3300000 usd
CY2023Q1 us-gaap Variable Lease Income
VariableLeaseIncome
3800000 usd
CY2024Q1 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
278698000 usd
CY2024Q1 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
367860000 usd
CY2024Q1 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
351473000 usd
CY2024Q1 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
329118000 usd
CY2024Q1 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
305441000 usd
CY2024Q1 sbra Lessor Operating Lease Payment To Be Received After Year Four
LessorOperatingLeasePaymentToBeReceivedAfterYearFour
1300476000 usd
CY2024Q1 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
2933066000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11400000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11600000 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
12400000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12500000 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 usd
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P17Y
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
996000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1802000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1324000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1347000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1330000 usd
CY2024Q1 sbra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
18104000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
24903000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12480000 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
12423000 usd
CY2024Q1 sbra Financing Receivable Number Of Loans
FinancingReceivableNumberOfLoans
14 loan
CY2024Q1 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
372620000 usd
CY2024Q1 us-gaap Notes Receivable Gross
NotesReceivableGross
369181000 usd
CY2023Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
369440000 usd
CY2024Q1 sbra Financing Receivable Fixed Interest Rate
FinancingReceivableFixedInterestRate
0.077
CY2024Q1 sbra Financing Receivable Effective Interest Rate
FinancingReceivableEffectiveInterestRate
0.076
CY2024Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6528000 usd
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6665000 usd
CY2024Q1 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
372620000 usd
CY2024Q1 us-gaap Notes Receivable Net
NotesReceivableNet
362653000 usd
CY2023Q4 us-gaap Notes Receivable Net
NotesReceivableNet
362775000 usd
CY2024Q1 sbra Preferred Equity Investments Number
PreferredEquityInvestmentsNumber
5 preferredequityinvestment
CY2024Q1 sbra Preferred Equity Investment Face Value
PreferredEquityInvestmentFaceValue
59632000 usd
CY2024Q1 sbra Preferred Equity Investment Carrying Amount
PreferredEquityInvestmentCarryingAmount
59819000 usd
CY2023Q4 sbra Preferred Equity Investment Carrying Amount
PreferredEquityInvestmentCarryingAmount
57849000 usd
CY2024Q1 sbra Preferred Equity Investment Weighted Average Contractual Rate
PreferredEquityInvestmentWeightedAverageContractualRate
0.110
CY2024Q1 sbra Preferred Equity Investment Weighted Average Effective Rate
PreferredEquityInvestmentWeightedAverageEffectiveRate
0.110
CY2024Q1 sbra Number Of Investments
NumberOfInvestments
19 investment
CY2024Q1 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
432252000 usd
CY2024Q1 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
422472000 usd
CY2023Q4 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
420624000 usd
CY2024Q1 sbra Investments Weighted Average Contractual Rate
InvestmentsWeightedAverageContractualRate
0.081
CY2024Q1 sbra Investments Weighted Average Effective Rate
InvestmentsWeightedAverageEffectiveRate
0.081
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6665000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6611000 usd
CY2024Q1 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
-137000 usd
CY2023Q1 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
-208000 usd
CY2024Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6528000 usd
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6403000 usd
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
28400000 usd
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
28500000 usd
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3100000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3000000 usd
CY2024Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
21300000 usd
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
16500000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1530000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2089000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
502147000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
248333000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
543026000 usd
CY2024Q1 sbra Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
1187402000 usd
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2484527000 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
4443000 usd
CY2024Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
16699000 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
2463385000 usd
CY2024Q1 sbra Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax
14330000 usd
CY2023Q1 sbra Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax
385000 usd
CY2024Q1 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
27135000 usd
CY2024Q1 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0 usd
CY2024Q1 us-gaap Derivative Assets
DerivativeAssets
27135000 usd
CY2024Q1 us-gaap Derivative Collateral Obligation To Return Securities
DerivativeCollateralObligationToReturnSecurities
0 usd
CY2024Q1 us-gaap Derivative Collateral Obligation To Return Cash
DerivativeCollateralObligationToReturnCash
0 usd
CY2024Q1 us-gaap Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral
DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral
27135000 usd
CY2024Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0 usd
CY2024Q1 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2024Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2024Q1 us-gaap Derivative Collateral Right To Reclaim Securities
DerivativeCollateralRightToReclaimSecurities
0 usd
CY2024Q1 us-gaap Derivative Collateral Right To Reclaim Cash
DerivativeCollateralRightToReclaimCash
0 usd
CY2024Q1 us-gaap Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral
0 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
18918000 usd
CY2023Q4 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0 usd
CY2023Q4 us-gaap Derivative Assets
DerivativeAssets
18918000 usd
CY2023Q4 us-gaap Derivative Collateral Obligation To Return Securities
DerivativeCollateralObligationToReturnSecurities
0 usd
CY2023Q4 us-gaap Derivative Collateral Obligation To Return Cash
DerivativeCollateralObligationToReturnCash
0 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral
DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral
18918000 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0 usd
CY2023Q4 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2023Q4 us-gaap Derivative Collateral Right To Reclaim Securities
DerivativeCollateralRightToReclaimSecurities
0 usd
CY2023Q4 us-gaap Derivative Collateral Right To Reclaim Cash
DerivativeCollateralRightToReclaimCash
0 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral
0 usd
CY2024Q1 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
372620000 usd
CY2023Q4 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
372873000 usd
CY2024Q1 sbra Preferred Equity Investment Face Value
PreferredEquityInvestmentFaceValue
59632000 usd
CY2023Q4 sbra Preferred Equity Investment Face Value
PreferredEquityInvestmentFaceValue
57681000 usd
CY2024Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2024Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2000000 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1400000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
26254000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231453564 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231164876 shares
CY2024Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1911467 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
233365031 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231164876 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04

Files In Submission

Name View Source Status
0001492298-24-000014-index-headers.html Edgar Link pending
0001492298-24-000014-index.html Edgar Link pending
0001492298-24-000014.txt Edgar Link pending
0001492298-24-000014-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sbra-20240331.htm Edgar Link pending
sbra-20240331.xsd Edgar Link pending
sbraex3112024q1.htm Edgar Link pending
sbraex3122024q1.htm Edgar Link pending
sbraex3212024q1.htm Edgar Link pending
sbra-20240331_def.xml Edgar Link unprocessable
sbra-20240331_lab.xml Edgar Link unprocessable
sbra-20240331_pre.xml Edgar Link unprocessable
sbra-20240331_htm.xml Edgar Link completed
sbraex3222024q1.htm Edgar Link pending
Show.js Edgar Link pending
sbra-20240331_cal.xml Edgar Link unprocessable